photo of

Details

Role Group Leader / Senior Research Fellow
Research area Genomic Medicine

Contact

Available for student supervision
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening...
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).

Top Publications

  • Pandelache, A, Francis, D, Oertel, R, Dickson, R, Sachdev, R, Ling, L, Gamage, D, Godler, DE. Detection of Cryptic Fragile X Full Mutation Alleles by Southern Blot in a Female and Her Foetal DNA via Chorionic Villus Sampling, Complicated by Mosaicism for 45,X0/46,XX/47,XXX.. Genes (Basel) 12(6) : 2021
    view publication
  • Jarmolowicz, AI, Baker, EK, Bartlett, E, Francis, D, Ling, L, Gamage, D, Delatycki, MB, Godler, DE. Fragile X syndrome full mutation in cognitively normal male identified as part of an Australian reproductive carrier screening program.. Am J Med Genet A 185(5) : 1498 -1503 2021
    view publication
  • Baker, EK, Butler, MG, Hartin, SN, Ling, L, Bui, M, Francis, D, Rogers, C, Field, MJ, Slee, J, Gamage, D, et al. Relationships between UBE3A and SNORD116 expression and features of autism in chromosome 15 imprinting disorders.. Transl Psychiatry 10(1) : 362 2020
    view publication
  • Kraan, CM, Baker, EK, Arpone, M, Bui, M, Ling, L, Gamage, D, Bretherton, L, Rogers, C, Field, MJ, Wotton, TL, et al. DNA Methylation at Birth Predicts Intellectual Functioning and Autism Features in Children with Fragile X Syndrome.. Int J Mol Sci 21(20) : 2020
    view publication
  • Baker, EK, Arpone, M, Kraan, C, Bui, M, Rogers, C, Field, M, Bretherton, L, Ling, L, Ure, A, Cohen, J, et al. FMR1 mRNA from full mutation alleles is associated with ABC-CFX scores in males with fragile X syndrome.. Sci Rep 10(1) : 11701 2020
    view publication

Page 5 of 15